Tech Curmudgeon · @joyctilton
91 followers · 926 posts · Server dragonscave.space

For all I know, however, it may have only been played on select public radio channels. I was hearing on based in San Mateo, Ca., around 1985/1986.

#TheWeb #kcsm #fm

Last updated 1 year ago

TumorBoardTuesday · @TumorBoardTuesday
114 followers · 2306 posts · Server mstdn.science

RT @AmandaNizamMD
A very timely discussion about adjuvant treatment of high-risk resected RCC.

In light of the recent press release about CONTACT-03, will be interesting to discuss management of recurrent RCC on or after adjuvant therapy. @HemOncFellows twitter.com/tumorboardtues/sta

#kcsm #OncTwitter

Last updated 2 years ago

TumorBoardTuesday · @TumorBoardTuesday
114 followers · 2306 posts · Server mstdn.science

RT @AmandaNizamMD
A very timely discussion about adjuvant treatment of high-risk resected RCC.

In light of the recent press release about CONTACT-03, will be interesting to discuss management of recurrent RCC on or after adjuvant therapy. @HemOncFellows twitter.com/tumorboardtues/sta

#kcsm #OncTwitter

Last updated 2 years ago

Queen Chinee · @RebeccaBoyce
332 followers · 1745 posts · Server toad.social
Queen Chinee · @RebeccaBoyce
327 followers · 1720 posts · Server toad.social

@allenmichie I don't want to change my instance, but I will follow anyone I see on jazztodon.
I have been a jazz fan since 1975. Growing up in and around Philly was wonderful.




#jazz #wrti #kcsm #wvia

Last updated 2 years ago

RT @_ShankarSiva@twitter.com

🧵1/ Wide adoption of SABR for primary is limited by long-term data. Online today @TheLancetOncol@twitter.com; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect@twitter.com for 50-day link: sciencedirect.com/science/arti

🐦🔗: twitter.com/_ShankarSiva/statu

#KidneyCancer #radonc #kcsm

Last updated 2 years ago

Freddy E Escorcia · @freddyeescorcia
83 followers · 128 posts · Server med-mastodon.com

Excellent 5-yr data on patients receiving stereotactic ablative radiotherapy for primary kidney cancer!

RT @_ShankarSiva@twitter.com

🧵1/ Wide adoption of SABR for primary is limited by long-term data. Online today @TheLancetOncol@twitter.com; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect@twitter.com for 50-day link: sciencedirect.com/science/arti

🐦🔗: twitter.com/_ShankarSiva/statu

#KidneyCancer #radonc #kcsm

Last updated 2 years ago